Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for LGND

Stock Name	Ligand Pharmaceuticals Incorporated
Ticker	LGND(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US53220K5048
LEI	5493008K7TB0IKP37H79

Show aggregate LGND holdings

News associated with LGND

Fidelity MSCI Health Care Index ETF -- Insider Buying Index Registering 19.3%: A look at the weighted underlying holdings of the Fidelity MSCI Health Care Index ETF (Symbol: FHLC) shows an impressive 19.3% of holdings on a weighted basis have experienced insider buying within the past six months. Illumina Inc (Symbol: ILMN), which makes up 0.27% of the F - 2025-09-09 10:54:08
Ligand Pharmaceuticals (NASDAQ:LGND) Given New $190.00 Price Target at Oppenheimer: Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) had its price objective upped by Oppenheimer from $167.00 to $190.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s target price points to a potential upside of 13.27% from the stock’s current price. A number of […] - 2025-09-05 05:03:20
Ligand Pharmaceuticals (NASDAQ:LGND) Sets New 52-Week High After Analyst Upgrade: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Thursday after Oppenheimer raised their price target on the stock from $167.00 to $190.00. Oppenheimer currently has an outperform rating on the stock. Ligand Pharmaceuticals traded as high as $166.99 and last traded at $166.54, with […] - 2025-09-04 02:18:55
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $157.00 Consensus Price Target from Brokerages: Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) have earned a consensus recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have covered the stock in the last […] - 2025-08-27 02:07:03
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Position Lowered by Maryland State Retirement & Pension System: Maryland State Retirement & Pension System decreased its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 13.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,519 shares of the biotechnology company’s stock after selling 844 shares during the period. Maryland State […] - 2025-08-15 04:50:59
Mutual of America Capital Management LLC Reduces Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Mutual of America Capital Management LLC lowered its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.8% in the first quarter, HoldingsChannel.com reports. The fund owned 2,752 shares of the biotechnology company’s stock after selling 110 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Ligand Pharmaceuticals were […] - 2025-08-13 06:48:50
Deutsche Bank AG Sells 1,087 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Deutsche Bank AG decreased its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 0.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 287,965 shares of the biotechnology company’s stock after selling 1,087 shares during the quarter. Deutsche Bank AG owned 1.49% […] - 2025-08-13 05:19:03
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Rating Upgraded by Wall Street Zen: Wall Street Zen upgraded shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) from a hold rating to a buy rating in a report published on Saturday. Several other analysts have also weighed in on LGND. Royal Bank Of Canada raised their price objective on Ligand Pharmaceuticals from $155.00 to $185.00 and gave the company an […] - 2025-08-12 04:12:53
Ligand Pharma Proposes Private Offering Of $400 Mln Of Sr. Notes: (RTTNews) - Ligand Pharmaceuticals Incorporated (LGND) Monday said it intends to privately offer $400 million of senior notes due 2030. - 2025-08-11 08:37:20
LGND Crosses Above Average Analyst Target: In recent trading, shares of Ligand Pharmaceuticals Inc (Symbol: LGND) have crossed above the average analyst 12-month target price of $144.75, changing hands for $146.32/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down - 2025-08-08 08:32:29
Insiders Buy the Holdings of TECB ETF: A look at the weighted underlying holdings of the iShares U.S. Tech Breakthrough Multisector ETF (TECB) shows an impressive 14.6% of holdings on a weighted basis have experienced insider buying within the past six months. Ligand Pharmaceuticals Inc (Symbol: LGND), which makes - 2025-07-29 10:45:36
Victory Capital Management Inc. Purchases 13,456 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Victory Capital Management Inc. lifted its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 94.6% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 27,678 shares of the biotechnology company’s stock after acquiring an additional 13,456 shares during the period. Victory Capital Management Inc.’s holdings in Ligand Pharmaceuticals were worth $2,910,000 […] - 2025-07-29 04:23:02
Mutual of America Capital Management LLC Cuts Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Mutual of America Capital Management LLC cut its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.8% during the first quarter, HoldingsChannel.com reports. The fund owned 2,752 shares of the biotechnology company’s stock after selling 110 shares during the period. Mutual of America Capital Management LLC’s holdings in Ligand Pharmaceuticals were […] - 2025-07-24 04:37:00
Arizona State Retirement System Acquires 110 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Arizona State Retirement System raised its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 2.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,407 shares of the biotechnology company’s stock after acquiring an additional 110 shares during the […] - 2025-07-22 07:06:52
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Sells $116,750.00 in Stock: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) Director John W. Kozarich sold 934 shares of Ligand Pharmaceuticals stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $125.00, for a total value of $116,750.00. Following the transaction, the director owned 46,456 shares of the company’s stock, valued […] - 2025-07-14 05:38:47
Oregon Public Employees Retirement Fund Cuts Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Oregon Public Employees Retirement Fund trimmed its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 2.3% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 4,342 shares of the biotechnology company’s stock after selling 100 shares during the quarter. Oregon Public Employees Retirement […] - 2025-07-09 05:43:24
Allspring Global Investments Holdings LLC Has $10.14 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Allspring Global Investments Holdings LLC decreased its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 96,419 shares of the biotechnology company’s stock after selling 3,643 shares during the quarter. Allspring Global […] - 2025-07-04 05:06:54
Illinois Municipal Retirement Fund Increases Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Illinois Municipal Retirement Fund increased its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 9.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,725 shares of the biotechnology company’s stock after purchasing an additional 902 […] - 2025-07-02 05:28:54
State of Alaska Department of Revenue Sells 269 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): State of Alaska Department of Revenue decreased its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 2.5% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 10,470 shares of the biotechnology company’s stock after selling 269 shares during the quarter. State of Alaska Department of Revenue’s holdings in Ligand Pharmaceuticals were worth […] - 2025-06-26 04:44:48
10.2% of VTWV Holdings Seeing Recent Insider Buys: A look at the weighted underlying holdings of the Vanguard Russell 2000 Value (VTWV) shows an impressive 10.2% of holdings on a weighted basis have experienced insider buying within the past six months. NBT Bancorp. Inc. (Symbol: NBTB), which makes up 0.17% of the Vanguard Rus - 2025-06-23 10:36:21
Opal Wealth Advisors LLC Purchases Shares of 305 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Opal Wealth Advisors LLC purchased a new stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund purchased 305 shares of the biotechnology company’s stock, valued at approximately $32,000. A number of other hedge funds have […] - 2025-06-17 04:58:58
Handelsbanken Fonder AB Has $700,000 Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Handelsbanken Fonder AB raised its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 13.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,658 shares of the biotechnology company’s stock after buying an additional 800 shares during […] - 2025-06-16 05:01:01
Rhumbline Advisers Trims Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Rhumbline Advisers cut its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 57,456 shares of the biotechnology company’s stock after selling 1,989 shares during the period. Rhumbline Advisers’ holdings in Ligand Pharmaceuticals […] - 2025-06-13 04:36:56
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $146.14 Average Price Target from Analysts: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) has earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have updated their coverage on the stock […] - 2025-06-13 02:32:49
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 10,563 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 26.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 50,401 shares of the biotechnology company’s stock after […] - 2025-06-03 05:13:09
Squarepoint Ops LLC Acquires Shares of 16,799 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Squarepoint Ops LLC acquired a new stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) during the fourth quarter, HoldingsChannel reports. The fund acquired 16,799 shares of the biotechnology company’s stock, valued at approximately $1,800,000. Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Smartleaf Asset Management […] - 2025-05-30 06:09:00
Bank of America Corp DE Has $11.51 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Bank of America Corp DE lifted its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 2.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 107,439 shares of the biotechnology company’s stock after buying an additional 2,533 shares during the quarter. Bank of America Corp DE’s holdings in Ligand Pharmaceuticals […] - 2025-05-23 04:36:48
Jane Street Group LLC Sells 1,083 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Jane Street Group LLC reduced its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 7.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,369 shares of the biotechnology company’s stock after selling 1,083 shares during the quarter. Jane Street Group LLC’s […] - 2025-05-20 04:30:46
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $146.14 Consensus Target Price from Analysts: Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) have earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have updated their coverage on the stock […] - 2025-05-19 02:14:54
The Manufacturers Life Insurance Company Increases Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): The Manufacturers Life Insurance Company increased its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 9.1% during the 4th quarter, Holdings Channel reports. The firm owned 9,373 shares of the biotechnology company’s stock after acquiring an additional 779 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Ligand Pharmaceuticals were worth […] - 2025-05-14 05:10:50

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) LGND holdings

Date	Number of LGND Shares Held	Base Market Value of LGND Shares	Local Market Value of LGND Shares	Change in LGND Shares Held	Change in LGND Base Value	Current Price per LGND Share Held	Previous Price per LGND Share Held
2025-12-03 (Wednesday)	13,817	USD 2,667,096	USD 2,667,096	0	USD -28,601	USD 193.03	USD 195.1
2025-12-02 (Tuesday)	13,817	USD 2,695,697	USD 2,695,697	495	USD 71,663	USD 195.1	USD 196.97
2025-12-01 (Monday)	13,322	USD 2,624,034	USD 2,624,034	0	USD -82,730	USD 196.97	USD 203.18
2025-11-28 (Friday)	13,322	USD 2,706,764	USD 2,706,764	33	USD -32,896	USD 203.18	USD 206.16
2025-11-27 (Thursday)	13,289	USD 2,739,660	USD 2,739,660	0	USD 0	USD 206.16	USD 206.16
2025-11-26 (Wednesday)	13,289	USD 2,739,660	USD 2,739,660	99	USD 55,231	USD 206.16	USD 203.52
2025-11-25 (Tuesday)	13,190	USD 2,684,429	USD 2,684,429	165	USD -10,313	USD 203.52	USD 206.89
2025-11-24 (Monday)	13,025	USD 2,694,742	USD 2,694,742	33	USD 106,346	USD 206.89	USD 199.23
2025-11-21 (Friday)	12,992	USD 2,588,396	USD 2,588,396	0	USD 2,598	USD 199.23	USD 199.03
2025-11-20 (Thursday)	12,992	USD 2,585,798	USD 2,585,798	-132	USD -118,402	USD 199.03	USD 206.05
2025-11-19 (Wednesday)	13,124	USD 2,704,200	USD 2,704,200	33	USD -6,292	USD 206.05	USD 207.05
2025-11-18 (Tuesday)	13,091	USD 2,710,492	USD 2,710,492	198	USD 114,486	USD 207.05	USD 201.35
2025-11-17 (Monday)	12,893	USD 2,596,006	USD 2,596,006	66	USD 19,575	USD 201.35	USD 200.86

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of LGND by Blackrock for IE00BDZVHG35

Show aggregate share trades of LGND

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-02 BUY 495 201.490 194.240 194.965 USD 96,508 130.00
2025-11-28 BUY 33 206.670 200.740 201.333 USD 6,644 129.31
2025-11-26 BUY 99 207.240 203.230 203.631 USD 20,159 128.55
2025-11-26 BUY 99 207.240 203.230 203.631 USD 20,159 128.55
2025-11-25 BUY 165 208.550 202.530 203.132 USD 33,517 128.17
2025-11-24 BUY 33 207.020 199.180 199.964 USD 6,599 127.78
2025-11-20 SELL -132 210.756 198.820 200.014 USD -26,402 127.05 Loss of -9,631 on sale
2025-11-19 BUY 33 208.050 203.470 203.928 USD 6,730 126.65
2025-11-18 BUY 198 208.820 199.000 199.982 USD 39,596 126.24
2025-11-17 BUY 66 207.320 200.824 201.473 USD 13,297 125.85
2025-11-14 BUY 33 205.320 198.515 199.196 USD 6,573 125.46
2025-11-12 BUY 33 209.990 201.540 202.385 USD 6,679 124.65
2025-11-10 BUY 33 209.300 201.500 202.280 USD 6,675 123.75
2025-11-06 BUY 33 211.915 186.960 189.456 USD 6,252 122.88
2025-11-04 BUY 33 191.455 186.280 186.797 USD 6,164 122.16
2025-10-30 BUY 165 188.770 184.440 184.873 USD 30,504 121.04
2025-10-29 BUY 66 184.520 191.880 191.144 USD 12,616 120.69
2025-10-22 SELL -132 185.570 187.810 187.586 USD -24,761 118.80 Loss of -9,080 on sale
2025-10-20 BUY 66 186.740 187.760 187.658 USD 12,385 118.02
2025-10-17 BUY 165 181.650 184.470 184.188 USD 30,391 117.65
2025-10-15 BUY 264 183.300 185.700 185.460 USD 48,961 117.27
2025-10-03 BUY 224 180.990 183.810 183.528 USD 41,110 116.52
2025-10-02 BUY 32 180.120 182.650 182.397 USD 5,837 116.14
2025-09-30 BUY 64 177.140 177.810 177.743 USD 11,376 115.40
2025-09-26 BUY 64 169.720 171.550 171.367 USD 10,967 114.72
2025-09-25 BUY 64 166.760 168.040 167.912 USD 10,746 114.40
2025-09-18 BUY 34 169.830 170.780 170.685 USD 5,803 114.06
2025-09-17 BUY 102 165.410 169.230 168.848 USD 17,222 113.74
2025-09-11 SELL -34 167.060 169.000 168.806 USD -5,739 113.08 Loss of -1,895 on sale
2025-09-10 BUY 68 165.970 166.960 166.861 USD 11,347 112.75
2025-07-17 SELL -68 137.570 137.840 137.813 USD -9,371 111.90 Loss of -1,762 on sale
2025-07-16 BUY 219 129.630 130.940 130.809 USD 28,647 111.78
2025-07-11 SELL -264 121.700 124.520 124.238 USD -32,799 111.53 Loss of -3,354 on sale
2025-07-02 BUY 1,815 113.660 114.680 114.578 USD 207,959 111.33
2025-06-25 BUY 66 115.720 118.250 117.997 USD 7,788 111.24
2025-06-20 BUY 236 114.070 114.940 114.853 USD 27,105 111.14
2025-06-11 BUY 64 115.390 116.400 116.299 USD 7,443 110.98
2025-06-10 BUY 64 113.420 114.950 114.797 USD 7,347 110.96
2025-06-04 SELL -32 103.800 103.980 103.962 USD -3,327 111.12 Profit of 229 on sale
2025-04-23 BUY 32 105.760 111.390 110.827 USD 3,546 113.05
2025-04-10 SELL -256 101.290 104.860 104.503 USD -26,753 113.87 Profit of 2,397 on sale
2025-04-08 SELL -32 96.670 102.700 102.097 USD -3,267 114.18 Profit of 387 on sale
2025-04-07 SELL -32 99.410 102.550 102.236 USD -3,272 114.35 Profit of 388 on sale
2025-04-04 SELL -160 99.570 101.150 100.992 USD -16,159 114.53 Profit of 2,165 on sale
2025-04-01 BUY 346 104.820 107.490 107.223 USD 37,099 114.71
2025-03-31 SELL -93 105.140 106.370 106.247 USD -9,881 114.83 Profit of 798 on sale
2025-03-21 BUY 583 108.150 111.860 111.489 USD 64,998 115.28
2025-03-14 SELL -480 106.190 109.250 108.944 USD -52,293 115.79 Profit of 3,287 on sale
2025-03-07 SELL -60 114.830 117.100 116.873 USD -7,012 116.33 Loss of -33 on sale
2025-03-04 SELL -30 115.260 117.870 117.609 USD -3,528 116.36 Loss of -37 on sale
2025-02-25 BUY 60 118.700 119.590 119.501 USD 7,170 116.33
2025-02-19 SELL -30 122.000 122.620 122.558 USD -3,677 116.03 Loss of -196 on sale
2025-02-13 BUY 90 113.930 115.990 115.784 USD 10,421 115.83
2025-02-12 BUY 30 111.390 112.660 112.533 USD 3,376 115.92
2025-02-11 BUY 120 112.770 114.750 114.552 USD 13,746 115.99
2024-12-30 SELL -808 105.760 109.460 109.090 USD -88,145 116.27 Profit of 5,798 on sale
2024-11-18 SELL -480 111.670 113.040 112.903 USD -54,193 112.97 Profit of 34 on sale
2024-11-08 SELL -32 121.250 127.260 126.659 USD -4,053 111.83 Loss of -475 on sale
2024-10-21 SELL -32 106.780 109.410 109.147 USD -3,493 0.00 Loss of -3,493 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-02	BUY	495	201.490	194.240	194.965	USD 96,508	130.00
2025-11-28	BUY	33	206.670	200.740	201.333	USD 6,644	129.31
2025-11-26	BUY	99	207.240	203.230	203.631	USD 20,159	128.55
2025-11-26	BUY	99	207.240	203.230	203.631	USD 20,159	128.55
2025-11-25	BUY	165	208.550	202.530	203.132	USD 33,517	128.17
2025-11-24	BUY	33	207.020	199.180	199.964	USD 6,599	127.78
2025-11-20	SELL	-132	210.756	198.820	200.014	USD -26,402	127.05 Loss of -9,631 on sale
2025-11-19	BUY	33	208.050	203.470	203.928	USD 6,730	126.65
2025-11-18	BUY	198	208.820	199.000	199.982	USD 39,596	126.24
2025-11-17	BUY	66	207.320	200.824	201.473	USD 13,297	125.85
2025-11-14	BUY	33	205.320	198.515	199.196	USD 6,573	125.46
2025-11-12	BUY	33	209.990	201.540	202.385	USD 6,679	124.65
2025-11-10	BUY	33	209.300	201.500	202.280	USD 6,675	123.75
2025-11-06	BUY	33	211.915	186.960	189.456	USD 6,252	122.88
2025-11-04	BUY	33	191.455	186.280	186.797	USD 6,164	122.16
2025-10-30	BUY	165	188.770	184.440	184.873	USD 30,504	121.04
2025-10-29	BUY	66	184.520	191.880	191.144	USD 12,616	120.69
2025-10-22	SELL	-132	185.570	187.810	187.586	USD -24,761	118.80 Loss of -9,080 on sale
2025-10-20	BUY	66	186.740	187.760	187.658	USD 12,385	118.02
2025-10-17	BUY	165	181.650	184.470	184.188	USD 30,391	117.65
2025-10-15	BUY	264	183.300	185.700	185.460	USD 48,961	117.27
2025-10-03	BUY	224	180.990	183.810	183.528	USD 41,110	116.52
2025-10-02	BUY	32	180.120	182.650	182.397	USD 5,837	116.14
2025-09-30	BUY	64	177.140	177.810	177.743	USD 11,376	115.40
2025-09-26	BUY	64	169.720	171.550	171.367	USD 10,967	114.72
2025-09-25	BUY	64	166.760	168.040	167.912	USD 10,746	114.40
2025-09-18	BUY	34	169.830	170.780	170.685	USD 5,803	114.06
2025-09-17	BUY	102	165.410	169.230	168.848	USD 17,222	113.74
2025-09-11	SELL	-34	167.060	169.000	168.806	USD -5,739	113.08 Loss of -1,895 on sale
2025-09-10	BUY	68	165.970	166.960	166.861	USD 11,347	112.75
2025-07-17	SELL	-68	137.570	137.840	137.813	USD -9,371	111.90 Loss of -1,762 on sale
2025-07-16	BUY	219	129.630	130.940	130.809	USD 28,647	111.78
2025-07-11	SELL	-264	121.700	124.520	124.238	USD -32,799	111.53 Loss of -3,354 on sale
2025-07-02	BUY	1,815	113.660	114.680	114.578	USD 207,959	111.33
2025-06-25	BUY	66	115.720	118.250	117.997	USD 7,788	111.24
2025-06-20	BUY	236	114.070	114.940	114.853	USD 27,105	111.14
2025-06-11	BUY	64	115.390	116.400	116.299	USD 7,443	110.98
2025-06-10	BUY	64	113.420	114.950	114.797	USD 7,347	110.96
2025-06-04	SELL	-32	103.800	103.980	103.962	USD -3,327	111.12 Profit of 229 on sale
2025-04-23	BUY	32	105.760	111.390	110.827	USD 3,546	113.05
2025-04-10	SELL	-256	101.290	104.860	104.503	USD -26,753	113.87 Profit of 2,397 on sale
2025-04-08	SELL	-32	96.670	102.700	102.097	USD -3,267	114.18 Profit of 387 on sale
2025-04-07	SELL	-32	99.410	102.550	102.236	USD -3,272	114.35 Profit of 388 on sale
2025-04-04	SELL	-160	99.570	101.150	100.992	USD -16,159	114.53 Profit of 2,165 on sale
2025-04-01	BUY	346	104.820	107.490	107.223	USD 37,099	114.71
2025-03-31	SELL	-93	105.140	106.370	106.247	USD -9,881	114.83 Profit of 798 on sale
2025-03-21	BUY	583	108.150	111.860	111.489	USD 64,998	115.28
2025-03-14	SELL	-480	106.190	109.250	108.944	USD -52,293	115.79 Profit of 3,287 on sale
2025-03-07	SELL	-60	114.830	117.100	116.873	USD -7,012	116.33 Loss of -33 on sale
2025-03-04	SELL	-30	115.260	117.870	117.609	USD -3,528	116.36 Loss of -37 on sale
2025-02-25	BUY	60	118.700	119.590	119.501	USD 7,170	116.33
2025-02-19	SELL	-30	122.000	122.620	122.558	USD -3,677	116.03 Loss of -196 on sale
2025-02-13	BUY	90	113.930	115.990	115.784	USD 10,421	115.83
2025-02-12	BUY	30	111.390	112.660	112.533	USD 3,376	115.92
2025-02-11	BUY	120	112.770	114.750	114.552	USD 13,746	115.99
2024-12-30	SELL	-808	105.760	109.460	109.090	USD -88,145	116.27 Profit of 5,798 on sale
2024-11-18	SELL	-480	111.670	113.040	112.903	USD -54,193	112.97 Profit of 34 on sale
2024-11-08	SELL	-32	121.250	127.260	126.659	USD -4,053	111.83 Loss of -475 on sale
2024-10-21	SELL	-32	106.780	109.410	109.147	USD -3,493	0.00 Loss of -3,493 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of LGND

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	110,984	0	159,903	69.4%
2025-09-18	117,054	13,457	140,913	83.1%
2025-09-17	81,005	0	103,214	78.5%
2025-09-16	92,697	0	112,565	82.3%
2025-09-15	86,010	12	107,580	79.9%
2025-09-12	68,288	0	104,615	65.3%
2025-09-11	60,509	301	71,159	85.0%
2025-09-10	35,593	223	59,633	59.7%
2025-09-09	101,282	28,400	147,520	68.7%
2025-09-08	32,301	0	42,928	75.2%
2025-09-05	72,289	25,659	90,824	79.6%
2025-09-04	34,071	290	39,292	86.7%
2025-09-03	55,981	3,084	64,953	86.2%
2025-09-02	33,298	1,247	54,732	60.8%
2025-08-29	49,378	1,324	60,183	82.0%
2025-08-28	41,100	1,122	50,668	81.1%
2025-08-27	42,612	533	53,754	79.3%
2025-08-26	30,554	16,905	44,556	68.6%
2025-08-25	52,529	226	57,736	91.0%
2025-08-22	79,217	27,200	96,318	82.2%
2025-08-21	26,493	73	34,681	76.4%
2025-08-20	34,995	100	48,398	72.3%
2025-08-19	34,424	1,314	46,478	74.1%
2025-08-18	57,773	4,412	84,246	68.6%
2025-08-15	110,176	26,500	135,284	81.4%
2025-08-14	88,175	29,505	111,162	79.3%
2025-08-13	106,251	11,400	149,502	71.1%
2025-08-12	1,046,591	263,275	1,291,167	81.1%
2025-08-11	379,969	0	465,623	81.6%
2025-08-08	43,704	1,589	96,370	45.4%
2025-08-07	96,752	7,844	131,275	73.7%
2025-08-06	81,719	0	98,017	83.4%
2025-08-05	31,915	2,291	55,506	57.5%
2025-08-04	27,475	3,500	42,040	65.4%
2025-08-01	43,001	0	53,660	80.1%
2025-07-31	58,147	0	89,224	65.2%
2025-07-30	44,784	6,207	72,410	61.8%
2025-07-29	26,036	0	34,478	75.5%
2025-07-28	21,430	933	37,717	56.8%
2025-07-25	31,566	875	41,560	76.0%
2025-07-24	21,577	1,183	36,717	58.8%
2025-07-23	41,043	6,123	51,663	79.4%
2025-07-22	69,081	1,504	90,344	76.5%
2025-07-21	139,754	6,798	166,003	84.2%
2025-07-18	77,882	8,200	132,441	58.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE